EPISODE · Apr 4, 2018 · 5 MIN
A Flawed Study Shows How Little We Understand Crispr's Effects
from Science, Spoken · host SpokenLayer
Biotech has been betting big on Crispr, the gene-editing technique that promises to snip away some of humanity’s worst diseases. But last May, a small case study suggested the much-hyped technology might actually be quite dangerous—and pop went the Crispr bubble, briefly tanking shares of Crispr companies like Editas Medicine, Intellia Therapeutics, and Crispr Therapeutics. Learn about your ad choices: dovetail.prx.org/ad-choices
What this episode covers
Biotech has been betting big on Crispr, the gene-editing technique that promises to snip away some of humanity’s worst diseases. But last May, a small case study suggested the much-hyped technology might actually be quite dangerous—and pop went the Crispr bubble, briefly tanking shares of Crispr companies like Editas Medicine, Intellia Therapeutics, and Crispr Therapeutics.
NOW PLAYING
A Flawed Study Shows How Little We Understand Crispr's Effects
No transcript for this episode yet
Similar Episodes
No similar episodes found.